Sarepta Therapeutics (SRPT) Interest Expenses (2017 - 2022)

Sarepta Therapeutics' Interest Expenses history runs 6 years deep, the most recent figure standing at $12.7 million for Q4 2022.

• In Q4 2022, Interest Expenses fell 20.86% year-over-year to $12.7 million; the TTM figure through Sep 2023 stood at $12.7 million (down 80.01% YoY), while the FY2023 annual figure was $22.0 million, down 58.67% from the prior year.
• Interest Expenses was $12.7 million for Q4 2022 at Sarepta Therapeutics, down from $14.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $20.6 million in Q3 2021 to a low of $172000.0 in Q1 2019.
• Historically, Interest Expenses has averaged $10.7 million across 5 years, with a median of $12.6 million in 2020.
• The sharpest annual moves came in 2019 and 2020: Interest Expenses plunged 97.75% in 2019, then surged 7815.7% in 2020.
• A 5-year view of Interest Expenses shows it stood at $2.3 million in 2018, then soared by 263.05% to $8.4 million in 2019, then climbed by 28.18% to $10.8 million in 2020, then soared by 49.23% to $16.0 million in 2021, then fell by 20.86% to $12.7 million in 2022.
• The last three Interest Expenses figures came in at $12.7 million (Q4 2022), $14.7 million (Q3 2022), and $17.0 million (Q2 2022), per Business Quant data.